Daniel J Cushing

Summary

Publications

  1. doi request reprint PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, Pennsylvania, United States
    Eur J Pharmacol 607:167-72. 2009
  2. doi request reprint Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, PA 19406, USA
    Clin Exp Pharmacol Physiol 39:3-8. 2012
  3. doi request reprint Bioequivalence of 2 intravenous amiodarone formulations in healthy participants
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, 1150 First Avenue, Suite 1050, King of Prussia, PA 19406, USA
    J Clin Pharmacol 49:407-15. 2009
  4. doi request reprint Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, PA 19406, USA
    Cardiovasc Toxicol 9:126-33. 2009
  5. doi request reprint The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, Pennsylvania, USA
    Clin Exp Pharmacol Physiol 37:358-61. 2010
  6. doi request reprint Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, Pennsylvania, USA
    Am J Cardiol 104:1152-7. 2009
  7. doi request reprint Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, PA, USA
    Eur J Pharmacol 635:165-70. 2010
  8. doi request reprint PM101: intravenous amiodarone formulation changes can improve medication safety
    Paul F Souney
    Prism Pharmaceuticals, Inc, 1016 West Ninth Avenue, Suite 130, King of Prussia, PA 19406, USA
    Expert Opin Drug Saf 9:319-33. 2010

Detail Information

Publications8

  1. doi request reprint PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, Pennsylvania, United States
    Eur J Pharmacol 607:167-72. 2009
    ..This study provides a useful model for the continued search for a safe and effective intravenous amiodarone formulation devoid of the hypotensive risk associated with the current commercial formulation...
  2. doi request reprint Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, PA 19406, USA
    Clin Exp Pharmacol Physiol 39:3-8. 2012
    ....
  3. doi request reprint Bioequivalence of 2 intravenous amiodarone formulations in healthy participants
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, 1150 First Avenue, Suite 1050, King of Prussia, PA 19406, USA
    J Clin Pharmacol 49:407-15. 2009
    ..Because the ratios and their CI fell between the limits of 0.8 and 1.25, bioequivalence of these 2 formulations was established. No safety concerns unique to PM101 were identified...
  4. doi request reprint Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs
    Daniel J Cushing
    Prism Pharmaceuticals Inc, King of Prussia, PA 19406, USA
    Cardiovasc Toxicol 9:126-33. 2009
    ..PM101 may represent a formulation of intravenous amiodarone that could be administered rapidly without dilution in the setting of life-threatening cardiac arrhythmias...
  5. doi request reprint The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, Pennsylvania, USA
    Clin Exp Pharmacol Physiol 37:358-61. 2010
    ..5. These data suggest that consideration should be given to intravenous amiodarone as a potential cause for sustained hypotension during prolonged infusion...
  6. doi request reprint Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans
    Daniel J Cushing
    Prism Pharmaceuticals, King of Prussia, Pennsylvania, USA
    Am J Cardiol 104:1152-7. 2009
    ..The absence of a hypotensive effect of AIV in this population suggests that further evaluation is needed in a patient population with cardiac disease...
  7. doi request reprint Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist
    Daniel J Cushing
    Prism Pharmaceuticals, Inc, King of Prussia, PA, USA
    Eur J Pharmacol 635:165-70. 2010
    ..It's utility as a bolus injection as well as infusion, its rapid efficacy and its rapid clearance make this an ideal candidate for clinical development...
  8. doi request reprint PM101: intravenous amiodarone formulation changes can improve medication safety
    Paul F Souney
    Prism Pharmaceuticals, Inc, 1016 West Ninth Avenue, Suite 130, King of Prussia, PA 19406, USA
    Expert Opin Drug Saf 9:319-33. 2010
    ..PM101 has been developed to address several of these important issues. Take home message: PM101 is a new formulation of A-IV that is stable in commonly used infusion materials and avoids co-solvent related toxicities...